Grifols slips as board rebuffs Brookfield’s $6.8B offer (update)
ADRs fell ~6% on Tuesday after its board of directors declined to recommend Brookfield Asset Management's (NYSE:BAM) ...
Grifols Board Issues Unfavorable Opinion on Brookfield Offer
Grifols SA’s board of directors said it won’t recommend that shareholders accept Brookfield Asset Management’s indicative ...
Grifols Signals It Would Reject $6.8 Billion Brookfield Bid (3)
Grifols SA’s board recommended that shareholders reject Brookfield Asset Management’s indicative offer, which values the ...
Grifols says potential Brookfield offer ‘significantly undervalues’ shares
Grifols (GRFS) informs that its board has held an extraordinary meeting this afternoon “without the intervention of the conflicted board ...
Brookfield considers US$6.9 billion bid for Grifols; shares dip
Brookfield Asset Management Ltd. is considering a €6.45 billion (US$6.9 billion) bid for Grifols SA, with the drug maker’s ...
Grifols spikes as banks reportedly finalize offers for buyout debt deal
Grifols (GRFS) stock gains as banks aim to finalize an €11B debt package for Brookfield's (BAM) plan to take the healthcare ...
Banks to Pitch Roughly €11 Billion Buyout Debt for Grifols
Banks are getting ready to submit final offers to Brookfield Asset Management for a debt package of about €11 billion ($11.6 ...
Mason Capital Reiterates Corporate Governance Shortcomings and Mismanagement of Grifols Under Current Board of Directors
Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of ...
Morningstar12d
Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors
Mason highlights numerous corporate governance failures that have resulted in Grifols’ depressed share price and a rumored transaction with affiliates of Brookfield Asset Management LP which ...
Seeking Alpha11d
Grifols holder Mason Capital against potential Brookfield deal
Grifols (NASDAQ:GRFS) holder Mason Capital said it's against a potential sale of the Spanish drugmaker to Brookfield Asset Management (BAM). Mason Capital, which has a 2.1% stake in Grifols (GRFS ...